<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6E027EE2-5EFA-4AF6-95E9-418A78350B32"><gtr:id>6E027EE2-5EFA-4AF6-95E9-418A78350B32</gtr:id><gtr:name>Oxygen Biotherapeutics, Inc.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FF89A43E-E57C-4243-8F82-707EF5360486"><gtr:id>FF89A43E-E57C-4243-8F82-707EF5360486</gtr:id><gtr:name>Aurum Biosciences ltd</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>College of Medical, Veterinary &amp;Life Sci</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6E027EE2-5EFA-4AF6-95E9-418A78350B32"><gtr:id>6E027EE2-5EFA-4AF6-95E9-418A78350B32</gtr:id><gtr:name>Oxygen Biotherapeutics, Inc.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FF89A43E-E57C-4243-8F82-707EF5360486"><gtr:id>FF89A43E-E57C-4243-8F82-707EF5360486</gtr:id><gtr:name>Aurum Biosciences ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/46AEDCA7-EE1E-463E-B540-243E29D0747E"><gtr:id>46AEDCA7-EE1E-463E-B540-243E29D0747E</gtr:id><gtr:firstName>Iseabail</gtr:firstName><gtr:otherNames>Mhairi</gtr:otherNames><gtr:surname>Macrae</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B73C976A-7524-4267-8964-B65169C69AD5"><gtr:id>B73C976A-7524-4267-8964-B65169C69AD5</gtr:id><gtr:firstName>Willy</gtr:firstName><gtr:surname>Gsell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D109226B-CB8C-4CA0-9178-FC91F3340B12"><gtr:id>D109226B-CB8C-4CA0-9178-FC91F3340B12</gtr:id><gtr:firstName>William</gtr:firstName><gtr:otherNames>Matthew</gtr:otherNames><gtr:surname>Holmes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/762ACFA0-8B24-4216-88F7-35B28948C9A3"><gtr:id>762ACFA0-8B24-4216-88F7-35B28948C9A3</gtr:id><gtr:firstName>Barrie</gtr:firstName><gtr:surname>Condon</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2EF0A273-EB0E-49A3-8C6E-D031EC7BF96E"><gtr:id>2EF0A273-EB0E-49A3-8C6E-D031EC7BF96E</gtr:id><gtr:firstName>Celestine</gtr:firstName><gtr:surname>Santosh</gtr:surname><gtr:orcidId>0000-0001-7305-3355</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D740E0E5-DDFA-4CF5-8043-2DEA41741D8B"><gtr:id>D740E0E5-DDFA-4CF5-8043-2DEA41741D8B</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>McCabe</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B9EC8CE2-2861-4183-99D2-BF0AF2524408"><gtr:id>B9EC8CE2-2861-4183-99D2-BF0AF2524408</gtr:id><gtr:firstName>Keith</gtr:firstName><gtr:surname>Muir</gtr:surname><gtr:orcidId>0000-0001-9535-022X</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700439"><gtr:id>5EA9F61A-4731-4026-963F-D13EA9AD2A51</gtr:id><gtr:title>Imaging the Ischaemic Penumbra using BOLD MRI with oxygen challenge as a metabolic biotracer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700439</gtr:grantReference><gtr:abstractText>Stroke is a major killer, and has a greater disability impact than any other chronic disease. Patients occupy one of the largest numbers of acute hospital bed days of any patient group (2.6 million per year), and the disease consumes between 4-6% of NHS expenditure (approx &amp;pound;2.8 billion) with costs projected to rise 30% by 2010 as life expectancy and survive rates increase. 

Treatment options are limited (clot busting drugs like rt-PA or aspirin) with less than 2% of stroke patients receiving rt-PA since it must be given within 3 hours of stroke for safety reasons, and patients must have a brain scan first to rule out brain haemorrhage. 

rt-PA is very effective in patients where brain damage has not fully evolved. In the first few hours after stroke, injured but potentially salvageable tissue (penumbra) can be saved by rt-PA. Penumbral tissue can be identified by magnetic resonance imaging (MRI), but current techniques underestimate penumbra size. If a rapid, more accurate MRI technique was available, more patients could be treated and recruitment into clinical trials to study new therapies, improved. This proposal describes development and validation of such a technique and provides preliminary MRI data from animal models and man.</gtr:abstractText><gtr:technicalSummary>Further development of acute stroke imaging is required to determine whether potentially salvageable tissue (penumbra) is still present, to improve treatment decisions for individual patients, and to enhance patient selection for clinical trials. An MRI-based technique which could disriminate between metabolically active and inactive tissue would represent a significant advance in physiological brain imaging and provide a means to study penumbral tissue and factors which influence its survival. This proposal describes such a technique, based on BOLD contrast and signal changes in brain associated with ventilating with 100% oxygen versus air which we believe will discriminate between ischaemic core and penumbra. BOLD contrast is sensitive to changes in oxy:deoxyhaemoglobin ratios during this ?oxygen challenge?. The planned studies will determine whether it can be developed to produce an improved technique for defining the ischaemic penumbra. Pilot experiments in animals and man provide novel and convincing data to support our hypothesis that oxygen can be used as a biotracer to identify metabolically active tissue within the ischaemic brain. 

The BOLD oxygen challenge technique (BOC) will be developed and validated using permanent middle cerebral artery occlusion (MCAO) in rats (Studies 1-3) and the consequences of reperfusion on identified penumbral tissue studied with transient MCAO (Study 4). Study 1: defining diffusion and perfusion thresholds for ischaemic damage and characterising tissue response to oxygen challenge over time. The response of ischaemic brain to BOC will be studied 1,2,3 &amp;amp; 4 hours post-MCAO to differentiate ischaemic core from penumbra and results compared with tissue injury assessed by diffusion-weighted imaging (DWI) and perfusion deficit assessed with arterial spin labelling (ASL). Study 2: Technique validation. Cerebral blood flow (CBF) and tissue oxygen levels will be recorded simultaneously within penumbral cortex during oxygen challenge to confirm that BOLD signal changes are related to oxygen utilisation by tissue and not to a change in CBF associated with changes in PaO2. Study 3: Confirming tissue viability within the defined penumbra. [14C] 2-deoxyglucose autoradiography will be used to confirm that tissue identified as penumbra by BOC, shows evidence of metabolic activity. Study 5: Consequences of reperfusion on penumbra. BOC, DWI and ASL conducted during ischaemia and following reperfusion to assess the consequences of reperfusion on tissue viability. In a separate group, BOC combined with assessment of perfusion deficit will define penumbral tissue, reperfusion will be induced and final infarct size determined (from T2) at day 7.</gtr:technicalSummary><gtr:fund><gtr:end>2011-03-09</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-03-10</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>224167</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oxygen Biotherapeutics, Inc.</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Research Agreement with US Biotechnology Company Oxygen Biotherapeutics now known as Tenax</gtr:description><gtr:id>A0CB98EE-6C01-4D62-8C2E-880311925F16</gtr:id><gtr:impact>The Chief Scientist Office in Edinburgh have awarded us a &amp;pound;225k grant to investigate the therapeutic potential of Oxycyte plus hyperoxia to treat acute stroke.

Wellcome Trust/ Department of Health, Health Innovations Challenge Fund award 2015- 2019. &amp;pound;1,816,033, GOLD imaging in acute stroke: further technology development incorporating a perfluorocarbon oxygen carrier (Oxycyte). Muir K &amp;amp; Santosh C (joint PIs), Macrae IM, Lees K, Deuchar G, Brenan D, Berwick J, Kennerly A, McConnachie A,</gtr:impact><gtr:outcomeId>gf4miDwmLK5-1</gtr:outcomeId><gtr:partnerContribution>Supply of GLP grade perfluorocarbon emulsion Oxycyte which has helped in securing grant support to take this research forward</gtr:partnerContribution><gtr:piContribution>We approached Oxygen Biotherapeutics to seek a research and commercial agreement with them and access to their perfuorocarbon Oxycyte which we will use for further development of the MRI acute stroke diagnostic technique which previously was funded by a MRC project grant.

The research agreement is now in place and we have received shipments of Oxycyte to support our research. The next phase in the development of our MRI theranostic will be funded by a Wellcome Trust Health Innovations Challenge Fund Award which will complete the pre-clinical research and will include a safety study in acute stroke patients. The start of this award is timed for when the spin out Company Aurum Biosciences has sufficient investment to receive the award.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aurum Biosciences ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>New research collaboration with spin out Aurum Biosciences</gtr:description><gtr:id>A9039182-BFB5-4120-8E49-910951CFFDE0</gtr:id><gtr:impact>First contract started in December 2015 so no outputs as yet</gtr:impact><gtr:outcomeId>56d84e28eea265.17787565-1</gtr:outcomeId><gtr:partnerContribution>The company provide the funding for further development of the stroke theranostic and the therapeutic (a perfluorocarbon emulsion) to us.</gtr:partnerContribution><gtr:piContribution>My research team provided the pre-clinical research for a successful application to the Wellcome Trust/Dept of Health Health Innovations Challenge Fund. This award supported the spin out of the Biotech Company Aurum Biosciences (From the University of Glasgow, Greater Glasgow and Clyde Health Board and Scottish Health Innovations Ltd). Aurum Biosciences is developing a new theranostic (combined therapeutic and diagnostic imaging) for stroke. We now collaborate with Aurum Biosciences delivering pre-clinical research studies through Industrial contracts with the Company.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>MRI evaluation of the ischaemic penumbra in a rodent stroke model</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3C74377B-7263-4C7F-AF51-6F5EBD8B1A7C</gtr:id><gtr:impact>Platform talk at 2nd Annual Scientific Session of the Chinese Stroke Association. The purpose was to make Chinese stroke clinicians and clinical scientists aware of our research and the development of our theranostic for acute stroke.</gtr:impact><gtr:outcomeId>58c6a538f1b2f7.53678582</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>World Stroke Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>952F108A-4785-4809-B13A-34A83854EC56</gtr:id><gtr:impact>Platform talk at World Stroke Congress, Hyderabad India 2016. Talk was also video-recorded and made available to people who were unable to attend the meeting</gtr:impact><gtr:outcomeId>58c6a4108144f6.41606198</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://world-stroke-academy.org/wso/#!*menu=6*browseby=8*sortby=1*media=1*ce_id=1071*ces_id=9998</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>symposium on stroke for academics and lay public</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A05F7113-B0E9-4F39-B71A-7B286E615898</gtr:id><gtr:impact>Whole event filmed and put on internet http://www.txbsi.com/ (click on 2008 symposium videos). V positive feedback received from academic audience and lay public

too early to judge impact but the local neurologist who organised the event appeared on local TV to publicise the event and educate the public about what to do in the event of a stroke</gtr:impact><gtr:outcomeId>4D3F355B274</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.txbsi.com/</gtr:url><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to Business leaders, Science Minister, Venture Capital funders</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EED589C5-5D92-4C96-BD03-5D4B8EF8D9AF</gtr:id><gtr:impact>Research from the grant has led to the development of a new technique to image stroke patients. Two younger members of our team entered the RCUK Business Plan competition to get commercial training and got through to the finals where they presented their Business Plan to Senior academics and industry leaders, venture capital funders and the University and Science Minister David Willetts.

This presentation will have publicised the economic and social burden associated with stroke and the development of new imaging techniques which could significantly address this problem and improve patient outcome. A number of Ventrure Capital groups would have been present in the audience as well as the media so this could lead to identification of further funding to develop the technique commercially. Our team were runners up in the competition, out of an initial 83 applications</gtr:impact><gtr:outcomeId>CHiBdvea7iZ</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visit to  National Centre for Biomedical Engineering Sciences, Galway</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D36DE57B-2888-4045-9978-18AFA0B455A5</gtr:id><gtr:impact>My lecture on Stroke, and an interview I gave relating to a career in neuroscience was videoed to put on the NBES Galway web site

The videos are designed to provide information to the public and to encourage school children to consider a career in Neuroscience</gtr:impact><gtr:outcomeId>825024EC9D4</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>9610</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Neuroscience Foundation Grant</gtr:description><gtr:end>2010-05-02</gtr:end><gtr:fundingOrg>The Neurosciences Foundation</gtr:fundingOrg><gtr:id>BBCC4736-5F51-4D36-8052-9F21EE986E87</gtr:id><gtr:outcomeId>958CB43E7130</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>224515</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Experimental and Translational Medicine Research Committee</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>Chief Scientist Office (CSO)</gtr:fundingOrg><gtr:id>507DC1AE-E649-4B4E-BEDC-A7BED4B732E7</gtr:id><gtr:outcomeId>Y7NohgMVXyf0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>248023</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Experimental and Translational Medicine Research Committee</gtr:description><gtr:end>2014-02-02</gtr:end><gtr:fundingOrg>Chief Scientist Office (CSO)</gtr:fundingOrg><gtr:fundingRef>ETM/146</gtr:fundingRef><gtr:id>0A14B18E-3C36-4F8E-B368-45B295F6D356</gtr:id><gtr:outcomeId>fSZy7Ncb6Zs0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>49778</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>EU FP 7 Network grant. FP7-HEALTH-2013-INNOVATION-1</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>Project No 603043</gtr:fundingRef><gtr:id>C5FB70C7-B62C-46C9-992F-A31486C25D56</gtr:id><gtr:outcomeId>tAerRbWNk2M</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1813033</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust/Department of Health - Health Innovations Challenge Fund</gtr:description><gtr:end>2019-01-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>78C56B1B-DD0E-4D33-AF1B-53F3DADF91CE</gtr:id><gtr:outcomeId>5461e2c52adfa6.83575694</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>279765</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wyeth Pharmaceuticals</gtr:department><gtr:description>TMRC Grant</gtr:description><gtr:end>2009-08-02</gtr:end><gtr:fundingOrg>Pfizer Ltd</gtr:fundingOrg><gtr:id>199CA90A-11BD-47F3-A379-4FDFA899B6CA</gtr:id><gtr:outcomeId>54189F8662B0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2008-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>389454</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Proof of Concept</gtr:description><gtr:end>2010-01-02</gtr:end><gtr:fundingOrg>Scottish Enterprise</gtr:fundingOrg><gtr:id>2EA2EEA6-876F-4EAD-B888-4EFE3720FCF7</gtr:id><gtr:outcomeId>08DF0E19D900</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Our MRI technique has been included in several reviews of advances in stroke imaging 2008 (Heiss W-D &amp;amp; Sorensen A G, Stroke 2009;40;e313-e314)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>A9EE5D2D-9406-4A87-87B9-13B3046238BE</gtr:id><gtr:outcomeId>Ghg8qVG3DNg</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>MRC funding supported the development and validation of the MRI imaging technique in rodent stroke models. Translation of the technique through to volunteers and a few acute stroke patients has also been carried out (Dani KA,et al., T2* Weighted Magnetic Resonance Imaging with Hyperoxia in Acute Ischemic Stroke. Annals Neurol 2010, 68(1):37-47.) Funding from Wellcome Trust Health Innovations Challenge Fund has just been awarded to complete the pre-clinical safety and efficacy for the combined imaging technique and therapy for acute stroke (theranostic) and to run a Phase II safety trial in stroke patients. 

The CSO funded research complements this research by providing data on pre-clinical efficacy of Oxycyte with hyperoxia in rodent stroke models</gtr:description><gtr:id>E3D6A3DE-CC42-4B6E-9C12-0A956AC84992</gtr:id><gtr:impact>Now that substantial funding has been secured to take the theranostic further, this novel technology has the potential to provide significant improvements on current techniques, providing direct rather than indirect assessment of tissue viability in the first hours after stroke and in addition, supporting potentially savageable tissue, providing a longer time window for successful therapeutic intervention and improved outcome for acute stroke patients</gtr:impact><gtr:outcomeId>E782B90D215</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>New MRI diagnostic technique for Acute Stroke</gtr:title><gtr:type>Diagnostic Tool - Imaging</gtr:type><gtr:url>http://www.aurumbiosciences.com/aurum/about.html</gtr:url><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Diagnostic MRI technique for acute stroke which combines an iv injection of an oxygen carrier and increased oxygen breathed by the patient. The delivery of oxygen also has a therapeutic use as it supports hypoxic tissue in the brain until flow through the blocked artery is restored.</gtr:description><gtr:id>3662BDE4-0842-4F92-8AA6-8C12F6ACFE82</gtr:id><gtr:impact>Diagnostic technique is still in development and therapeutic efficacy currently being tested pre-clinically. However, the basic principle of increased O2 ventilation during MRI scanning, has been translated through to clinical research by our group and tested on a small group of acute stroke patients. (Dani KA, et al, T2* Weighted Magnetic Resonance Imaging with Hyperoxia in Acute Ischemic Stroke. Annals Neurol (2010) 68(1):37-47)</gtr:impact><gtr:outcomeId>76FA3CEB773</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Development of a new theranostic for acute stroke.  Combined therapy &amp; MRI diagnostic technique</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type><gtr:url>http://www.aurumbiosciences.com/aurum/about.html</gtr:url></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Aurum Biosciences Ltd</gtr:companyName><gtr:description>AURUM Biosciences Ltd was established in 2010 as a spin-out medical imaging diagnostic and therapeutic company from Scottish Health Innovations Limited (SHIL), University of Glasgow and GGHB. The company was established as a result of the clear unmet medical need and the business opportunity in the area of stroke, together with the exciting discoveries in identifying the penumbra using novel MRI techniques developed by Dr Santosh and team [published and unpublished].

All members of Company are still salaried by the University, SHIL or NHS GGHB.</gtr:description><gtr:id>2A3FD4CD-180E-4B37-A464-C5DD9B83EE55</gtr:id><gtr:impact>The theranostic product is still under development so impacts to-date relate to scientific publications describing the technology.</gtr:impact><gtr:outcomeId>oTCcRCKmmYz</gtr:outcomeId><gtr:url>http://www.aurumbiosciences.com/</gtr:url><gtr:yearCompanyFormed>2010</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>AECE5D7E-8A05-41B5-89C4-423B4030F1E9</gtr:id><gtr:title>The IMPROVE Guidelines. Ischaemia Models: Procedural Refinements Of in Vivo Experiments</gtr:title><gtr:parentPublicationTitle>Journal of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de61b0e9c52c66b05f0febaeb3c965eb"><gtr:id>de61b0e9c52c66b05f0febaeb3c965eb</gtr:id><gtr:otherNames> Percie du Sert N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>58c69fc0758b53.22422057</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE4612B4-EB4B-4036-8892-9F9FA1309172</gtr:id><gtr:title>Differences in the evolution of the ischemic penumbra in stroke-prone spontaneously hypertensive and Wistar-Kyoto rats.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4319dfcd8ef4be50b24fbceb03f6bfac"><gtr:id>4319dfcd8ef4be50b24fbceb03f6bfac</gtr:id><gtr:otherNames>McCabe C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>3E257000_83E257000_8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB343B65-E24F-4AB7-9A8E-0B1211ACA522</gtr:id><gtr:title>Preclinical stroke research--advantages and disadvantages of the most common rodent models of focal ischaemia.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3eba03e97bd1fcfbc86a14f9e17f3328"><gtr:id>3eba03e97bd1fcfbc86a14f9e17f3328</gtr:id><gtr:otherNames>Macrae IM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>pm_12655_25_21457227</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0102B48D-70A5-4CED-AF2A-DFBF8B32026C</gtr:id><gtr:title>Detection of ischemic penumbra using combined perfusion and T2* oxygen challenge imaging.</gtr:title><gtr:parentPublicationTitle>International journal of stroke : official journal of the International Stroke Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b05765c0435ef842efccfcb9033d316c"><gtr:id>b05765c0435ef842efccfcb9033d316c</gtr:id><gtr:otherNames>Robertson CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1747-4930</gtr:issn><gtr:outcomeId>5461e766744149.53733372</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>691812CA-D2BB-42A4-87D5-EC16B37DD49F</gtr:id><gtr:title>T2*-weighted magnetic resonance imaging with hyperoxia in acute ischemic stroke.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a891b124da452d7be6028107d76c80d"><gtr:id>2a891b124da452d7be6028107d76c80d</gtr:id><gtr:otherNames>Dani KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>LgwUvm95JRr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C7B9162-0D73-43B9-8132-B7EE961EEB7F</gtr:id><gtr:title>Stroke penumbra defined by an MRI-based oxygen challenge technique: 1. Validation using [14C]2-deoxyglucose autoradiography.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b05765c0435ef842efccfcb9033d316c"><gtr:id>b05765c0435ef842efccfcb9033d316c</gtr:id><gtr:otherNames>Robertson CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>AESbsfQ7osy</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07E2D7FA-7A6C-4DFA-92FE-93A41B80542F</gtr:id><gtr:title>Potential use of oxygen as a metabolic biosensor in combination with T2*-weighted MRI to define the ischemic penumbra.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c011fa60523cc89e7b1baf065d33f1c"><gtr:id>6c011fa60523cc89e7b1baf065d33f1c</gtr:id><gtr:otherNames>Santosh C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>036D92FD07A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E78AAB8-9684-4C9D-B46D-F86120C87C73</gtr:id><gtr:title>ESC-BRAIN: experimental and clinical stroke research--do they connect?. Meeting report of the ESC-BRAIN joint symposium held in London and Shanghai in May 2013.</gtr:title><gtr:parentPublicationTitle>Cerebrovascular diseases (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d7fb06edfb9f77f45f51b6c2af414e7"><gtr:id>6d7fb06edfb9f77f45f51b6c2af414e7</gtr:id><gtr:otherNames>Baron JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1015-9770</gtr:issn><gtr:outcomeId>pm_12655_25_24192895</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5D79D9F-C217-4DE8-B3FB-A3C4D62EBA72</gtr:id><gtr:title>Translational perspectives on perfusion-diffusion mismatch in ischemic stroke.</gtr:title><gtr:parentPublicationTitle>International journal of stroke : official journal of the International Stroke Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7875e6670b0b5a9e09acb3035dbb89b8"><gtr:id>7875e6670b0b5a9e09acb3035dbb89b8</gtr:id><gtr:otherNames>Campbell BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1747-4930</gtr:issn><gtr:outcomeId>bRt4KuRhKft</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E16C67EC-8638-47F1-8B40-1A603B3CCD4F</gtr:id><gtr:title>The influence of gender on 'tissue at risk' in acute stroke: A diffusion-weighted magnetic resonance imaging study in a rat model of focal cerebral ischaemia.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8ad1c7bf4016ad7b98d2c50dc7946d6"><gtr:id>b8ad1c7bf4016ad7b98d2c50dc7946d6</gtr:id><gtr:otherNames>Baskerville TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>56d70103718749.08979398</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1627FC6B-063B-48AC-A71B-10FF2F0DA393</gtr:id><gtr:title>Oxygen challenge magnetic resonance imaging in healthy human volunteers.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a891b124da452d7be6028107d76c80d"><gtr:id>2a891b124da452d7be6028107d76c80d</gtr:id><gtr:otherNames>Dani KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>56d700ce64bbf8.39961620</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DD83D57-F225-4C54-B7B8-40C2D5132090</gtr:id><gtr:title>Noninvasive MRI measurement of CBF: evaluating an arterial spin labelling sequence with 99mTc-HMPAO CBF autoradiography in a rat stroke model.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8ad1c7bf4016ad7b98d2c50dc7946d6"><gtr:id>b8ad1c7bf4016ad7b98d2c50dc7946d6</gtr:id><gtr:otherNames>Baskerville TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>pm_12655_25_22472604</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A457342-6574-424D-84CD-33F4B39CBCBF</gtr:id><gtr:title>Influence of 100% and 40% oxygen on penumbral blood flow, oxygen level, and T2*-weighted MRI in a rat stroke model.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8ad1c7bf4016ad7b98d2c50dc7946d6"><gtr:id>b8ad1c7bf4016ad7b98d2c50dc7946d6</gtr:id><gtr:otherNames>Baskerville TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>PHnwRq3mqkd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A37B85C-A79F-49FC-BB18-3A87C09B8093</gtr:id><gtr:title>Stroke penumbra defined by an MRI-based oxygen challenge technique: 2. Validation based on the consequences of reperfusion.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b05765c0435ef842efccfcb9033d316c"><gtr:id>b05765c0435ef842efccfcb9033d316c</gtr:id><gtr:otherNames>Robertson CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>SmbLXkHHaoV</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700439</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>A77DAE3A-499B-4F46-971D-6C82F51F9C2E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Stroke</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>